跳转至内容
Merck

Y0001400

氨己烯酸

European Pharmacopoeia (EP) Reference Standard

别名:

(±)-Vigabatrin, (R,S)-4-氨基-5-己烯酸, (±)-γ-乙烯基-GABA, (±)-4-氨基己酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H11NO2
CAS号:
分子量:
129.16
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

vigabatrin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

InChI 密鑰

PJDFLNIOAUIZSL-UHFFFAOYSA-N

基因資訊

human ... ABAT(18)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Vigabatrin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

不可逆的 GABA 转氨酶抑制剂。增加神经末梢的胞内 GABA 浓度;具有抗癫痫活性。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

STOT RE 1

標靶器官

Eyes,Central nervous system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Danièle Bentué-Ferrer et al.
Therapie, 65(1), 23-27 (2010-03-09)
Vigabatrin is a second generation anticonvulsant drug available in France since 1995. It is an amino acid analogue of the GABA, marketed under the racemic form [R(-)/S(+)50/50], but only the S(+)-enantiomer is active. Neither the mechanism of action of vigabatrin
E Ben-Menachem
Acta neurologica Scandinavica. Supplementum, (192)(192), 5-15 (2011-11-09)
Discovered more than three decades ago, vigabatrin is approved in more than 50 countries as adjunctive therapy for adult patients with refractory complex partial seizures who have responded inadequately to several alternative treatments and as monotherapy for pediatric patients aged
Justin A Tolman et al.
Expert opinion on pharmacotherapy, 10(18), 3077-3089 (2009-12-04)
Vigabatrin (Sabril) was approved in the USA in mid-2009 for the adjunctive treatment of refractory complex partial seizures and as treatment of infantile spasms. Vigabatrin's more than 30-year history of research and development is condensed into a clinically relevant review
S D Walker et al.
Acta neurologica Scandinavica. Supplementum, (192)(192), 72-82 (2011-11-09)
Vigabatrin is an effective antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS). In clinical trials, vigabatrin was generally well-tolerated with an adverse event profile similar to that of other AEDs. The most
J M Pellock
Acta neurologica Scandinavica. Supplementum, (192)(192), 83-91 (2011-11-09)
Vigabatrin is an effective and well-tolerated antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS), but its benefits must be evaluated in conjunction with its risk of retinopathy with the development of peripheral

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门